Researchers have identified a promising new strategy to treat autoimmune diseases by targeting a specific molecular interaction within immune cells.
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused ...
A new class of drug compounds, called ENDOtollins, reduce harmful inflammation while maintaining the body’s ability to fight infections.
First-in-class molecules block a specific protein interaction in immune cells, offering a potential targeted approach to ...
Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the ...
Morning Overview on MSN
New molecules curb inflammation while preserving key immune defenses
Researchers at Brigham and Women’s Hospital have identified a new class of small molecules that selectively shut down ...
In 2012, the New York Times interviewed Brad Bailey at the Republican National Convention about his efforts to get the party ...
SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it has received a formal Request for ...
Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the body's ...
Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results